Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.

Acute myeloid leukemia (AML) cells are relatively resistant to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL). We previously reported that triptolide, a potent anticancer agent from a Chinese herb, decreases XIAP in leukemic cells. We evaluated the combination of triptolide and TRAIL and found synergistic promotion of apoptosis in AML cells. XIAP-overexpressing U937 cells (U937XIAP) were more resistant to TRAIL than U937neo cells, and inhibition of XIAP with the small-molecule inhibitor 1396-11 enhanced TRAIL-induced apoptosis, implying XIAP as a resistance factor in AML. Furthermore, triptolide increased DR5 levels in OCI-AML3, while the DR5 increase was blunted in p53-knockdown OCI-AML3 and p53-mutated U937 cells, confirming a role for p53 in the regulation of DR5. In support of this finding, disruption of MDM2-p53 binding with subsequent increase in p53 levels by nutlin3a increased DR5 levels and sensitized OCI-AML3 cells to TRAIL. The combination of 1396-11 plus nutlin3a plus TRAIL was more effective than either the 1396-11 and TRAIL or nutlin3a and TRAIL combinations in OCI-AML3 cells, further supporting the role of triptolide as a sensitizer to TRAIL-induced apoptosis in part by independent modulation of XIAP expression and p53 signaling. Thus, the combination of triptolide and TRAIL may provide a novel strategy for treating AML by overcoming critical mechanisms of apoptosis resistance.

[1]  James T. Elder,et al.  A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. , 2006, Cancer research.

[2]  Z. Estrov,et al.  Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. , 2006, Blood.

[3]  R. Herbst,et al.  A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. López-Rivas,et al.  The mitogen-activated protein kinase pathway can inhibit TRAIL-induced apoptosis by prohibiting association of truncated Bid with mitochondria , 2006, Cell Death and Differentiation.

[5]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[6]  W. Plunkett,et al.  Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. , 2005, Blood.

[7]  D. Gilliland,et al.  Drug therapy for acute myeloid leukemia. , 2005, Blood.

[8]  W. Shao-xi,et al.  Clinical observation on effect of triptolide tablet in treating patients with psoriasis vulgaris , 2005 .

[9]  G. Pond,et al.  Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. , 2005, Blood.

[10]  B. Fang,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in cancer , 2005, Cancer Gene Therapy.

[11]  Seung U. Kim,et al.  Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP , 2005, Oncogene.

[12]  Hua Yu,et al.  Elimination of Hepatic Metastases of Colon Cancer Cells via p53-Independent Cross-Talk between Irinotecan and Apo2 Ligand/TRAIL , 2004, Cancer Research.

[13]  S. Agrawal,et al.  Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics , 2004, Oncogene.

[14]  M. Smyth,et al.  TRAIL and its receptors as targets for cancer therapy , 2004, Cancer science.

[15]  Jorge A. Almenara,et al.  Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation , 2004, Leukemia.

[16]  A. Ashkenazi,et al.  Targeting death receptors in cancer with Apo2L/TRAIL. , 2004, Current opinion in pharmacology.

[17]  K. Kinzler,et al.  X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. , 2004, Cancer research.

[18]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[19]  H. Sung,et al.  Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. , 2003, Blood.

[20]  U. Moll,et al.  The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.

[21]  M. Andreeff,et al.  Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia , 2003, Leukemia.

[22]  J. A. Ross,et al.  PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. , 2003, Molecular cancer therapeutics.

[23]  John Calvin Reed,et al.  PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2 , 2003, Oncogene.

[24]  I. Jeremias,et al.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.

[25]  L. Foroni,et al.  Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor‐related apoptosis‐inducing ligand , 2003, British journal of haematology.

[26]  S. Korsmeyer,et al.  Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. , 2003, Cancer research.

[27]  G. Rosen,et al.  Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-κB activation , 2002, Experimental & Molecular Medicine.

[28]  R. Sellers,et al.  Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  S. Fulda,et al.  Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.

[30]  Peter Schow,et al.  Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax , 2002, Nature Medicine.

[31]  B. Wong,et al.  Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-κB activation in gastric cancer cells , 2001, Oncogene.

[32]  Z. Wang,et al.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.

[33]  B. Vandenbunder,et al.  Rel/NF-κB Transcription Factors Protect against Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Up-regulating the TRAIL Decoy Receptor DcR1* , 2001, The Journal of Biological Chemistry.

[34]  P. Daniel,et al.  The kiss of death: promises and failures of death receptors and ligands in cancer therapy , 2001, Leukemia.

[35]  R. Ho,et al.  Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. , 2001, Cancer research.

[36]  J. A. Ross,et al.  Triptolide and Chemotherapy Cooperate in Tumor Cell Apoptosis , 2001, The Journal of Biological Chemistry.

[37]  W. El-Deiry,et al.  p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. , 2001, Experimental cell research.

[38]  Benny J Chen,et al.  Triptolide, A Novel Immunosuppressive and Anti-Inflammatory Agent Purified from a Chinese Herb Tripterygium Wilfordii Hook F , 2001, Leukemia & lymphoma.

[39]  K. Bhalla,et al.  Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. , 2000, Blood.

[40]  Z. Estrov,et al.  The prognostic significance of p16INK4a/p14ARF locus deletion and MDM‐2 protein expression in adult acute myelogenous leukemia , 2000, Cancer.

[41]  D. Kufe,et al.  XIAP Regulates DNA Damage-induced Apoptosis Downstream of Caspase-9 Cleavage* , 2000, The Journal of Biological Chemistry.

[42]  J C Reed,et al.  Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  W. El-Deiry,et al.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.

[44]  J. Dichgans,et al.  Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. , 1999, Biochemical and biophysical research communications.

[45]  M. Seldin,et al.  Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. , 1999, Blood.

[46]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[47]  G. Rosen,et al.  PG490 (Triptolide) Cooperates with Tumor Necrosis Factor-α to Induce Apoptosis in Tumor Cells* , 1999, The Journal of Biological Chemistry.

[48]  P. Kao,et al.  Immunosuppressant PG490 (Triptolide) Inhibits T-cell Interleukin-2 Expression at the Level of Purine-box/Nuclear Factor of Activated T-cells and NF-κB Transcriptional Activation* , 1999, The Journal of Biological Chemistry.

[49]  C. Prives.  Signaling to p53 Breaking the MDM2–p53 Circuit , 1998, Cell.

[50]  Y. Yang,et al.  Triptolide induces apoptotic death of T lymphocyte. , 1998, Immunopharmacology.

[51]  A. Fornace,et al.  p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. , 1998, Cancer research.

[52]  P. Lipsky,et al.  A potential new treatment for rheumatoid arthritis: thunder god vine. , 1997, Seminars in arthritis and rheumatism.

[53]  J. Pezzuto,et al.  Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. , 1997, Cancer letters.

[54]  D. Huhn,et al.  Analysis of the p53 and MDM‐2 gene in acute myeloid leukemia , 1996, European journal of haematology.

[55]  D. Green,et al.  Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl , 1995, The Journal of experimental medicine.

[56]  S. Stass,et al.  The human MDM-2 oncogene is overexpressed in leukemias. , 1993, Blood.

[57]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[58]  T. Panichakul,et al.  Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis. , 2006, Anticancer research.

[59]  A. Fornace,et al.  p53dependent and -independent Regulation of the Death Receptor KILLER/DR5 Gene Expression in Response to Genotoxic Stress and Tumor Necrosis Factor a , 2006 .

[60]  Yungui Wang,et al.  Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. , 2005, Leukemia research.

[61]  Robin Foà,et al.  TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. , 2005, Haematologica.

[62]  Shao-xi Wu,et al.  Clinical observation on effect of triptolide tablet in treating patients with psoriasis vulgaris. , 2005, Chinese journal of integrative medicine.

[63]  Clemencia Pinilla,et al.  Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. , 2004, Cancer cell.

[64]  Lurong Zhang,et al.  Triptolide inhibits the growth and metastasis of solid tumors. , 2003, Molecular cancer therapeutics.

[65]  J. Tschopp,et al.  Protein-based therapeutic approaches targeting death receptors , 2003, Cell Death and Differentiation.

[66]  岡野 宏.  Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma , 2003 .

[67]  B. Dörken,et al.  In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity , 2001, Leukemia.

[68]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[69]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.